Video

Optimizing Radiation Therapy in Hodgkin Lymphoma

For High-Definition, Click

Long-term side effects are the leading concern when administering radiation therapy in early-stage Hodgkin lymphoma. However, these side effects often do not manifest for 10 to 20 years following treatment, which complicates studies examining optimal treatment approaches. As a result, Jonathan W. Friedberg, MD, believes that long-term follow-up from trials examining first-line treatment approaches will be more revealing than shorter analyses.

The standard approach for administering radiation has evolved significantly from extended-field radiation to the current standard of involved-field radiation, Craig H. Moskowitz, MD says. This new approach applies radiation only to the affected lymph node, which has been shown to be equally effective and less toxic than extended-field radiation. Longer follow up is still pending to ascertain if these approaches reduce the occurrence of long-term side effects.

Related Videos
Justin M. Watts, MD
Mazyar Shadman, MD, MPH
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study